FDA Alerts
FDA Approves First Anti-Diarrheal Drug for HIV/AIDS Patients
The US Food and Drug Administration today approved Fulyzaq ( crofelemer ) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.
Diarrhea is experienced by many HIV/AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies. Fulyzaq is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite.
Patients take Fulyzaq two times a day to manage watery diarrhea due to the secretion of electrolytes ...
FDA issues Safety Alert on Intestinomicina
The US Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections.
FDA Safety Alert on Intestinomicina
The US Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections.
Proton Pump Inhibitors and Stomach Acid
The U.S. Food and Drug Administration (FDA) is informing the public that the use of stomach acid drugs known as proton pump inhibitors ( PPIs ) may be associated with an increased risk of Clostridium difficile–associated diarrhea ( CDAD ).
FDA approves treatment for Clostridium difficile infection
The U.S. Food and Drug Administration today approved Dificid ( fidaxomicin ) tablets for the treatment of Clostridium difficile-associated diarrhea ( CDAD ).
New Test Detecting Diarrhea-Causing Infection
The FDA has approved a test that detects an infection that causes diarrhea, other intestinal problems and sometimes death.